Laura Deming

Laura Deming is a venture capitalist and scientist known for her work in the field of biotechnology and longevity. Born in 1992 in New Zealand, Deming developed an early interest in the biology of aging, which led her to pursue this passion through advanced education and professional endeavors aimed at extending the human lifespan.

Early Life and Education

Laura Deming was homeschooled before attending the Massachusetts Institute of Technology (MIT) at the age of 14. Her precocious interest in the science of aging motivated her to join the lab of Cynthia Kenyon, a prominent figure in the field of aging research, at the University of California, San Francisco (UCSF) when she was just 12 years old. Deming later became a Thiel Fellow, a program founded by entrepreneur Peter Thiel that grants young innovators $100,000 to pursue their ideas in lieu of completing their college education.

Career

Laura Deming's career is distinguished by her focus on the science of longevity. After receiving the Thiel Fellowship, she founded The Longevity Fund, a venture capital firm that invests in companies developing therapies to extend human healthspan and lifespan. The Longevity Fund has been instrumental in providing early-stage funding to a number of startups in the biotechnology sector, with a specific emphasis on those tackling the biological processes of aging.

In addition to her venture capital work, Deming has been involved in various initiatives aimed at fostering innovation in the field of longevity. She has advocated for increased investment and research in technologies that could potentially delay aging or reverse its effects, contributing to the growing interest in longevity science as a viable field of study and investment.

Impact and Contributions

Laura Deming's contributions to the field of longevity and biotechnology are significant. Through The Longevity Fund, she has played a crucial role in supporting early-stage biotech companies focused on aging. Her work has not only provided essential capital to these startups but has also helped to legitimize the field of longevity science within the broader scientific and investment communities.

Deming's advocacy for longevity research has also contributed to a broader public understanding and interest in the potential for science to extend healthy human life. She is frequently cited in discussions about the future of aging and the ethical implications of life extension technologies.

See Also

• Biotechnology
• Venture Capital
• Aging
• Thiel Fellowship
• Cynthia Kenyon